The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Nilotinib-Global Market Insights and Sales Trends 2025
Synopsis
Nilotinib is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI).
The global Nilotinib market size is expected to reach US$ 1200.7 million by 2029, growing at a CAGR of -5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Nilotinib in various end use industries. The expanding demands from the Hospital, Drugs Store and Other, are propelling Nilotinib market. 50mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 200mg segment is estimated at % CAGR for the next seven-year period.
Tasigna, a targeted therapy used in the treatment of certain types of leukemia, is witnessing increasing demand. Factors driving market growth include the rising incidence of leukemia, advancements in precision medicine, and the efficacy of Tasigna in treating resistant forms of the disease. Key players in the market are investing in research and development to expand the indications of Tasigna and explore its potential in combination therapies. Additionally, strategic collaborations and regulatory approvals are contributing to market expansion. However, challenges such as high treatment costs and the availability of generic alternatives may impact market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nilotinib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nilotinib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nilotinib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nilotinib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nilotinib covered in this report include Novartis. etc.
The global Nilotinib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Global Nilotinib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nilotinib market, Segment by Type:
50mg
200mg
Other
Global Nilotinib market, by Application
Hospital
Drugs Store
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Nilotinib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Nilotinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Nilotinib is a type of targeted cancer drug called a tyrosine kinase inhibitor (TKI).
The global Nilotinib market size is expected to reach US$ 1200.7 million by 2029, growing at a CAGR of -5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Nilotinib in various end use industries. The expanding demands from the Hospital, Drugs Store and Other, are propelling Nilotinib market. 50mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 200mg segment is estimated at % CAGR for the next seven-year period.
Tasigna, a targeted therapy used in the treatment of certain types of leukemia, is witnessing increasing demand. Factors driving market growth include the rising incidence of leukemia, advancements in precision medicine, and the efficacy of Tasigna in treating resistant forms of the disease. Key players in the market are investing in research and development to expand the indications of Tasigna and explore its potential in combination therapies. Additionally, strategic collaborations and regulatory approvals are contributing to market expansion. However, challenges such as high treatment costs and the availability of generic alternatives may impact market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Nilotinib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Nilotinib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Nilotinib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Nilotinib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Nilotinib covered in this report include Novartis. etc.
The global Nilotinib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Global Nilotinib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Nilotinib market, Segment by Type:
50mg
200mg
Other
Global Nilotinib market, by Application
Hospital
Drugs Store
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Nilotinib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Nilotinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Nilotinib Market Overview
1.1 Nilotinib Product Overview
1.2 Nilotinib Market Segment by Type
1.2.1 50mg
1.2.2 200mg
1.2.3 Other
1.3 Global Nilotinib Market Size by Type
1.3.1 Global Nilotinib Market Size Overview by Type (2018-2029)
1.3.2 Global Nilotinib Historic Market Size Review by Type (2018-2023)
1.3.3 Global Nilotinib Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Nilotinib Sales Breakdown by Type (2018-2023)
1.4.2 Europe Nilotinib Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Nilotinib Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Nilotinib Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Nilotinib Sales Breakdown by Type (2018-2023)
2 Global Nilotinib Market Competition by Company
2.1 Global Top Players by Nilotinib Sales (2018-2023)
2.2 Global Top Players by Nilotinib Revenue (2018-2023)
2.3 Global Top Players by Nilotinib Price (2018-2023)
2.4 Global Top Manufacturers Nilotinib Manufacturing Base Distribution, Sales Area, Product Type
2.5 Nilotinib Market Competitive Situation and Trends
2.5.1 Nilotinib Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Nilotinib Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Nilotinib as of 2022)
2.7 Date of Key Manufacturers Enter into Nilotinib Market
2.8 Key Manufacturers Nilotinib Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Nilotinib Status and Outlook by Region
3.1 Global Nilotinib Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Nilotinib Historic Market Size by Region
3.2.1 Global Nilotinib Sales in Volume by Region (2018-2023)
3.2.2 Global Nilotinib Sales in Value by Region (2018-2023)
3.2.3 Global Nilotinib Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Nilotinib Forecasted Market Size by Region
3.3.1 Global Nilotinib Sales in Volume by Region (2024-2029)
3.3.2 Global Nilotinib Sales in Value by Region (2024-2029)
3.3.3 Global Nilotinib Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Nilotinib by Application
4.1 Nilotinib Market Segment by Application
4.1.1 Hospital
4.1.2 Drugs Store
4.1.3 Other
4.2 Global Nilotinib Market Size by Application
4.2.1 Global Nilotinib Market Size Overview by Application (2018-2029)
4.2.2 Global Nilotinib Historic Market Size Review by Application (2018-2023)
4.2.3 Global Nilotinib Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Nilotinib Sales Breakdown by Application (2018-2023)
4.3.2 Europe Nilotinib Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Nilotinib Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Nilotinib Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Nilotinib Sales Breakdown by Application (2018-2023)
5 North America Nilotinib by Country
5.1 North America Nilotinib Historic Market Size by Country
5.1.1 North America Nilotinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Nilotinib Sales in Volume by Country (2018-2023)
5.1.3 North America Nilotinib Sales in Value by Country (2018-2023)
5.2 North America Nilotinib Forecasted Market Size by Country
5.2.1 North America Nilotinib Sales in Volume by Country (2024-2029)
5.2.2 North America Nilotinib Sales in Value by Country (2024-2029)
6 Europe Nilotinib by Country
6.1 Europe Nilotinib Historic Market Size by Country
6.1.1 Europe Nilotinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Nilotinib Sales in Volume by Country (2018-2023)
6.1.3 Europe Nilotinib Sales in Value by Country (2018-2023)
6.2 Europe Nilotinib Forecasted Market Size by Country
6.2.1 Europe Nilotinib Sales in Volume by Country (2024-2029)
6.2.2 Europe Nilotinib Sales in Value by Country (2024-2029)
7 Asia-Pacific Nilotinib by Region
7.1 Asia-Pacific Nilotinib Historic Market Size by Region
7.1.1 Asia-Pacific Nilotinib Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Nilotinib Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Nilotinib Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Nilotinib Forecasted Market Size by Region
7.2.1 Asia-Pacific Nilotinib Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Nilotinib Sales in Value by Region (2024-2029)
8 Latin America Nilotinib by Country
8.1 Latin America Nilotinib Historic Market Size by Country
8.1.1 Latin America Nilotinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Nilotinib Sales in Volume by Country (2018-2023)
8.1.3 Latin America Nilotinib Sales in Value by Country (2018-2023)
8.2 Latin America Nilotinib Forecasted Market Size by Country
8.2.1 Latin America Nilotinib Sales in Volume by Country (2024-2029)
8.2.2 Latin America Nilotinib Sales in Value by Country (2024-2029)
9 Middle East and Africa Nilotinib by Country
9.1 Middle East and Africa Nilotinib Historic Market Size by Country
9.1.1 Middle East and Africa Nilotinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Nilotinib Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Nilotinib Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Nilotinib Forecasted Market Size by Country
9.2.1 Middle East and Africa Nilotinib Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Nilotinib Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Nilotinib Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Nilotinib Products Offered
10.1.5 Novartis Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Nilotinib Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Nilotinib Industrial Chain Analysis
11.4 Nilotinib Market Dynamics
11.4.1 Nilotinib Industry Trends
11.4.2 Nilotinib Market Drivers
11.4.3 Nilotinib Market Challenges
11.4.4 Nilotinib Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Nilotinib Distributors
12.3 Nilotinib Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
